Thursday, 7 July 2022
  
Login

Australia's most trusted
source of pharma news

Thursday, 07 July 2022
Listen to this story 
News

Novo battles off-label Ozempic

Posted 19 May 2022 AM

Unable to keep up with the off-label demand for Ozempic being used as a 'miracle' weight loss drug, Novo Nordisk has demanded the drug to be prioritised for its approved use.

In a joint statement developed with the TGA and relevant stakeholders, Novo said, "the shortage is significantly affecting people using Ozempic for its approved used for type 2 diabetes".

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (7)

Sales & Customer Relations (26)

Access & Reimbursement (2)

Clinical & Medical, R&D (14)

Regulatory, Pharmacovigilance & QA (8)

Devices (1)

Other (29)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.